Jade Biosciences, Inc. Segments Disclosure
17. Segment Reporting
The Company has one reportable segment relating to the research and development of its programs, JADE101, JADE201, and JADE301. The Company’s chief operating decision maker (“CODM”), its , manages the Company’s operations on a consolidated basis and uses consolidated net loss for the allocation of resources and the assessment of performance. Although the Company’s financial reporting package that is reviewed and approved by the CODM disaggregates significant expenses such as program-level external research and development costs, personnel costs, including stock-based compensation expense, and professional and consulting fees, all decisions made by the CODM are based upon reviewing operating metrics and performance indicators at the Company-wide consolidated level and consolidated net loss. The CODM uses consolidated net loss to evaluate loss generated from the Company’s business activities in deciding how to allocate company resources and in monitoring budget versus actual results. Assets are also managed on a Company-wide consolidated basis.
The table below is a summary of the significant expenses categories regularly provided to the CODM (in thousands):
|
|
Twelve Months Ended |
|
|
Period from |
|
||
Operating Expenses |
|
|
|
|
|
|
||
JADE101 external research and development costs |
|
$ |
28,943 |
|
|
$ |
22,992 |
|
JADE201 external research and development costs |
|
|
24,249 |
|
|
|
2,437 |
|
JADE301 external research and development costs |
|
|
8,897 |
|
|
|
2,141 |
|
Research and development personnel-related costs |
|
|
28,560 |
|
|
|
3,509 |
|
Other research and development costs |
|
|
2,472 |
|
|
|
155 |
|
General and administrative personnel-related costs |
|
|
12,691 |
|
|
|
1,714 |
|
Professional and consulting fees |
|
|
6,933 |
|
|
|
2,253 |
|
Other general and administrative costs |
|
|
797 |
|
|
|
337 |
|
Total operating expenses |
|
$ |
113,542 |
|
|
$ |
35,538 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 6, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.